COLL vs ETON
COLL: A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds on its opioid franchise. ETON: Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting ultra-rare genetic and metabolic disorders.
Side-by-side fundamentals
| Metric | COLL | ETON | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.72 | $43.58 | |
| Market cap as of 2026-07-23 | $1.1B | $1.2B | |
| P/E as of 2026-07-23 | 15.05 | n/a | |
| PEG as of 2026-07-23 | 13.08 | n/a | |
| Net margin as of 2026-07-23 | +9.4% | -1.7% | COLL higher |
| Gross margin as of 2026-07-23 | +60.7% | +54.8% | COLL higher |
| Operating margin as of 2026-07-23 | +21.7% | +2.4% | COLL higher |
| ROE as of 2026-07-23 | +26.7% | -5.7% | COLL higher |
| ROA as of 2026-07-23 | +4.6% | -1.5% | COLL higher |
| Debt / equity as of 2026-07-23 | 2.57 | 1.00 | ETON lower |
| Revenue growth (YoY) as of 2026-07-23 | +19.9% | +79.9% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +18.9% | +55.5% | ETON higher |
| Beta as of 2026-07-23 | 0.77 | 0.89 | |
| 1-year return as of 2026-07-22 close | +16.0% | +200.0% | ETON higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.